Abstracts tagged "inflammatory arthritis"

Abstract Number: 3265 • 2015 ACR/ARHP Annual Meeting
Sustaining Employment with Arthritis: Can Existing Workplace Policies and Accommodations Make a Difference?
Monique A.M. Gignac^1,2, Elizabeth M. Badley³, Dorcas Beaton⁴, Vicki Kristman⁵, Cameron Mustard⁶, Peter Smith⁶ and Selahadin Ibrahim⁶, ¹Instititue for Work and Health, Toronto, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³Toronto Western Research Institute, Toronto, ON, Canada, ⁴St. Michael's Hospital, Toronto, ON, Canada, ⁵Lakehead University, Toronto, ON, Canada, ⁶Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Despite improved treatment, many individuals with inflammatory arthritis (IA) and osteoarthritis (OA) report difficulties working, reduced productivity and elevated absenteeism. Lacking is research on…
Abstract Number: 189 • 2015 ACR/ARHP Annual Meeting
Indocyanine Green (ICG) -Enhanced Fluorescence Optical Imaging (FOI) in Patients with Active Rheumatoid Arthritis; A Comparative Study with Ultrasound and Association with Biomarkers
Shin-ya Kawashiri^1,2, Ayako Nishino³, Masataka Umeda³, Shoichi Fukui¹, Yoshikazu Nakashima³, Naoki Iwamoto¹, Kunihiro Ichinose¹, Hideki Nakamura¹, Tomoki Origuchi⁴, Kiyoshi Aoyagi² and Atsushi Kawakami³, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁴Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Methods: Twenty-five active RA patients (mean disease durations 7.5 years and DAS28-ESR 5.90) who fulfilled 2010 RA classification criteria were consecutively enrolled in this study.…
Abstract Number: 3266 • 2015 ACR/ARHP Annual Meeting
Keeping Baby Boomers in the Labour Force Longer: What Does It Mean for Workers with Arthritis?
Monique A.M. Gignac¹, Elizabeth M. Badley², Dorcas Beaton³, Vicki Kristman⁴, Cameron Mustard⁵, Peter Smith⁵ and Selahadin Ibrahim⁵, ¹Instititue for Work and Health, Toronto, ON, Canada, ²Toronto Western Research Institute, Toronto, ON, Canada, ³St. Michael's Hospital, Toronto, ON, Canada, ⁴Lakehead University, Toronto, ON, Canada, ⁵Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: There is concern that an aging workforce results in lost skills and high burden on pension programs. This has resulted in the dissolution of…
Abstract Number: 201 • 2015 ACR/ARHP Annual Meeting
Innate Lymphoid Cells Are Present at Normal Human Enthesis Providing a Potential Mechanism for Spondyloarthropathy Pathogenesis
Richard Cuthbert¹, Evangelos M. Fragkakis¹, Peter Millner², Robert Dunsmuir², Yasser El-Sherbiny¹ and Dennis McGonagle¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Department of Spinal Surgery, National Health Service, Leeds, United Kingdom
Background/Purpose: The pathogenesis of murine spondyloarthropathy (SpA) has been intimately linked to the presence of IL-23 responsive, innate like lymphocytes at peripheral and spinal enthesis.…
Abstract Number: 479 • 2015 ACR/ARHP Annual Meeting
How to Recruit Anti-CCP Positive Patients from Primary Care
Jackie L. Nam¹, Laura Hunt¹, Elizabeth M.A. Hensor¹ and Paul Emery^1,2, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: Around 1% of the population test positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies. This biomarker predicts progression to rheumatoid arthritis (RA) but over a…
Abstract Number: 933 • 2015 ACR/ARHP Annual Meeting
DEK-Targeting DNA Aptamers As Novel Therapeutics for Inflammatory Arthritis
Nirit Mor-Vaknin¹, Anjan K. Saha², Maureen Legendre¹, Carmelo Carmona-Rivera³, M. Asif Amin⁴, Bradley J. Rabquer⁵, Marta J. Gonzalez-Hernandez⁶, Julie M. Jorns⁷, Srilakshmi Yalavarthi⁸, Smriti Mohan⁹, Dave Pai¹⁰, Kristine Angevine¹¹, Barbara Adams¹², Jason S. Knight⁸, Alisa E. Koch^13,14,15, David Fox¹⁴, Dave Engelke¹⁶, Mariana J. Kaplan¹⁷ and David Markovitz⁴, ¹Infectious Diseases, University of Michigan, Ann Arbor, MI, ²Medical School, University of Michigan, Ann Arbor, MI, ³Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Internal Medicine, University of Michigan, Ann Arbor, MI, ⁵Albion College, Ann Arbor, MI, ⁶Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, ⁷Pathology, University of Michigan, Ann Arbor, MI, ⁸Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁹Pediatric Rheumatology, University of Michigan, Ann Arbor, MI, ¹⁰Scripps Research Institute, San Diego, CT, ¹¹Appistry, Inc, St. Louis, MO, ¹²Pediatric Rheum PTD, Univ of Michigan Hlth System, Ann Arbor, MI, ¹³VA Medical Service, Ann Arbor, MI, ¹⁴Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ¹⁵Internal Medicine, Veteran's Affairs and University of Michigan, Ann Arbor, MI, ¹⁶Biochemistry, University Michigan, Ann Arbor, MI, ¹⁷Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Aptamers are short single stranded DNA or RNA oligonucleotides that are specifically selected to bind and neutralize a wide range of biomedically relevant proteins.…
Abstract Number: 2307 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Disease Prevention in Rheumatologic Disease: Assessing Screening in a Primary Care Setting
Micaela Bayard¹ and Magdalena Cadet², ¹Rheumatology, New York Hospital of Queens/ Weill Cornell Medical Center, New York, NY, ²Rheumatology and Immunology, Duke University School of Medicine, Durham, NC
Background/Purpose: To determine the proportion of patients diagnosed with rheumatologic disease receiving preventive health care according to US Preventive Services Task Force recommendations with emphasis…
Abstract Number: 2140 • 2014 ACR/ARHP Annual Meeting
Agreement Among FDG-PET/CT, Ultrasound and Physical Examination in Patients with Inflammatory Arthritis
Alexis Ogdie¹, Shiv Sehra², Viviane Khoury³, Yihui Jiang⁴, Shawn Rose⁵, Nehal N. Mehta⁶, Sally W. Pullman-Mooar⁷, Abass Alavi⁸, Joel Gelfand⁹ and Joshua Baker¹⁰, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Department of Radiology, University of Pennsylvania, Philadelphia, PA, ⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁶Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, ⁷Rheumatology, University of Pennsylvania and Philadelphia Veterans Hospital, Philadelphia, PA, ⁸Department of Radiology/Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, ⁹Dermatology and Epidemiology, University of Pennsylvania., Philadelphia, PA, ¹⁰Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA
Background/Purpose: The lack of tools to accurately measure and quantify joint inflammation is a challenging problem in the study of inflammatory arthritis. No gold standard…
Abstract Number: 1074 • 2014 ACR/ARHP Annual Meeting
A Meta-Analysis of the Risk of Venous Thromboembolism in Inflammatory Rheumatic Diseases
Jason J Lee¹ and Janet E. Pope², ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²St Joseph Health Care, London, ON, Canada
Background/Purpose: We performed a meta-analysis investigating the risk of developing deep vein thrombosis (DVT) and/or pulmonary embolisms (PE) in patients with inflammatory arthritis, vasculitis, and…
Abstract Number: 1006 • 2014 ACR/ARHP Annual Meeting
Interleukin-4 As Promising, Anti-Inflammatory Transgene for Gene Therapeutic Application in Joint Diseases
Annemarie Lang¹, Johannes Neuhaus², Moritz Pfeiffenberger³, Erik Schroeder⁴, Frank Buttgereit⁵, Michael F. G. Schmidt³ and Timo Gaber⁶, ¹Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, ²Department of Veterinary Medicine, Research Center of Medical Technology and Biotechnology, Bad Langensalza, Germany, ³Department of Veterinary Medicine, Institute of Immunology, Freie Universität Berlin, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁵Charité University Hospital, Berlin, Germany, ⁶Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany
Background/Purpose Interleukin- 4 (IL-4), a Th2-cell released immunomodulatory factor, has potent chondroprotective and anti-inflammatory properties able to inhibit the synthesis of IL-1β and TNFα, and…
Abstract Number: 937 • 2014 ACR/ARHP Annual Meeting
A Unique Role for IL-18 Receptor-α in Monocyte Migration in RA and K/BxN Serum Transfer Arthritis
W. Alexander Stinson¹, Phillip L. Campbell¹, Jeffrey Ruth², Gautam Edhayan², Ray A. Ohara², Nicholas Lepore³, Alisa E. Koch⁴, David A. Fox² and M. Asif Amin², ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³University of Michigan, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Department of Veteran's Affairs and University of Michigan, Ann Arbor, MI
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by monocyte (MN) recruitment. Proinflammatory cytokines and their corresponding receptors play an important role in…
Abstract Number: 400 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of 14-3-3η in the Evaluation of Inflammatory Arthritis
Lance Feller¹, Paul Tuttle IV² and Terry L. Moore³, ¹Rheumatology, Saint Louis University, St. Louis, MO, ²Rheumatology, Saint Louis University, Saint Louis, MO, ³Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO
Background/Purpose 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…
Abstract Number: 415 • 2014 ACR/ARHP Annual Meeting
a Dual-Center, Double Blind Randomized Study for a New Scientific Approach in Assessment of Tender Joints in Inflammatory Arthritis Using the Smart Joint Assessor Glove Device (Smart JAG Device)
Mohammad Khan¹, Larry Willis², Swapan Nath³, Cheryl Guest², Lindsey Gillispie⁴ and Mary Jane Rorick⁴, ¹Arthritis & Rheumatology Center of Oklahoma, Oklahoma City, OK, ²Research, Arthritis & Rheumatology Center of Oklahoma, PLLC, Oklahoma City, OK, ³Department of Pediatrics and Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Rheumatology, McBride Orthopedic Hospital, Oklahoma City, OK
Background/Purpose Tender Joint Count (TJC) is a vital quality measure to assess the progression of Inflammatory Arthritis both from a therapeutic and a diagnostic standpoint.…
Abstract Number: 333 • 2014 ACR/ARHP Annual Meeting
Deletion of the Prolactin Receptor Aggravates the Course of Antigen-Induced Arthritis
Norma Adan, Maria G. Ledesma-Colunga, Ana L. Reyes-Lopez, Fernando Lopez-Barrera, Gonzalo Martinez de la Escalera and Carmen Clapp, Institute of Neurobiology, National University of Mexico (UNAM), Queretaro, Mexico
Background/Purpose: Prolactin (PRL), the hormone essential for lactation, may protect against joint damage in rheumatoid arthritis. PRL frequently increases in the circulation of patients with…
Abstract Number: 183 • 2014 ACR/ARHP Annual Meeting
Musculoskeletal Ultrasound Reveals Calcific Deposition Arthropathy in Seronegative Inflammatory Arthritis Patients
Sheila L. Arvikar¹, Janice Lin² and Minna J. Kohler³, ¹Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ²Dermatology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Allergy, and Immunology, Massachusetts General Hospital / Harvard Medical School, Boston, MA
Background/Purpose Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) have vastly improved the diagnosis of rheumatoid arthritis (RA), but the diagnosis and management of seronegative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].